Cytokine-induced killer (CIK) cell therapy in breast, ovarian, and cervical cancer: a systematic review of clinical evidence with emerging opportunities

Abstract Background Cytokine-induced killer (CIK) cell therapy, a form of adoptive immunotherapy, is gaining increasing attention and has been explored in multiple tumor types. This systematic review highlights the current clinical evidence for CIK-based therapies in breast, ovarian, and cervical cancer. Methods A PubMed search (up to August 2025) identified clinical studies on CIK or DC-CIK therapies in ovarian, cervical, and breast cancers, including a total of 14 studies with 2,650 patients. Methodological quality and risk of bias were appraised using design-specific JBI Critical Appraisal Tools. Results CIK therapy, especially when combined with standard treatments, was associated with improved survival outcomes and immune responses in a predominantly retrospective evidence base, with mostly mild and manageable side effects. Breast cancer represents the largest evidence base, with the greatest number of studies and patients. Conclusions Overall, CIK therapy holds potential across the malignancies included in this review, though additional trials are required to optimize treatment and combinations. With the recent establishment of the International Society of CIK Cells (ISCC), further advances in CIK-based cancer immunotherapy are anticipated.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-12
DOI
https://doi.org/10.1186/s12885-026-17219-0
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cytokine-induced killer (CIK) cell therapy in breast, ovarian, and cervical cancer: a systematic review of clinical evidence with emerging opportunities

Alexander Mustea, Ingo G.H. Schmidt‐Wolf, Hanna Strauch
BMC Cancer
CAR-T cell therapy research
article

Cytokine-induced killer (CIK) cell therapy in breast, ovarian, and cervical cancer: a systematic review of clinical evidence with emerging opportunities

Alexander Mustea, Ingo G.H. Schmidt‐Wolf, Hanna Strauch
article en

Abstract

Abstract Background Cytokine-induced killer (CIK) cell therapy, a form of adoptive immunotherapy, is gaining increasing attention and has been explored in multiple tumor types. This systematic review highlights the current clinical evidence for CIK-based therapies in breast, ovarian, and cervical cancer. Methods A PubMed search (up to August 2025) identified clinical studies on CIK or DC-CIK therapies in ovarian, cervical, and breast cancers, including a total of 14 studies with 2,650 patients. Methodological quality and risk of bias were appraised using design-specific JBI Critical Appraisal Tools. Results CIK therapy, especially when combined with standard treatments, was associated with improved survival outcomes and immune responses in a predominantly retrospective evidence base, with mostly mild and manageable side effects. Breast cancer represents the largest evidence base, with the greatest number of studies and patients. Conclusions Overall, CIK therapy holds potential across the malignancies included in this review, though additional trials are required to optimize treatment and combinations. With the recent establishment of the International Society of CIK Cells (ISCC), further advances in CIK-based cancer immunotherapy are anticipated.

BMC Cancer
University Hospital Bonn (DE)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon